- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.11. | Daiichi Sankyo launches its STING operation against cancer | ||
| 11.11. | Ireland's Mallinckrodt closes spinout, rebrands as Keenova | ||
| 11.11. | Queer Eye's Tan France to front Lilly obesity campaign | ||
| 11.11. | AHA: MSD's oral PCSK9 matches injectables | ||
| 10.11. | Roche's oral MS hope fenebrutinib hits the mark in phase 3 | ||
| 10.11. | AHA: AZ's baxdrostat impresses in resistant hypertension | ||
| 10.11. | AHA: Cash for drug adherence study has disappointing result | ||
| 07.11. | Intellia shares fall after hospitalised CRISPR patient dies | ||
| 07.11. | Braveheart, AAVantgarde rounds head recent biofinancings | ||
| 07.11. | Eisai settles Lenvima patent dispute with Torrent Pharma | ||
| 07.11. | GLP-1s feature in second batch of national priority vouchers | ||
| 06.11. | Novo, Lilly sign MFN pricing deal with Trump administration | ||
| 06.11. | J&J adds first new indication for Caplyta since takeover | ||
| 06.11. | Lilly reports 20% weight loss with amylin-targeting drug | ||
| 06.11. | AZ's Q3 sales reach record $15bn, but it holds guidance | ||
| 06.11. | Novo Nordisk fights back with oral GLP-1 data in obesity | ||
| 06.11. | Pfizer said to have matched Novo's $10bn bid for Metsera | ||
| 05.11. | Psychedelic merger to create AtaiBeckley completes | ||
| 05.11. | Dismay as FDA declines to approve Biohaven's ataxia drug | ||
| 05.11. | UK facing alarming loss of scientific talent overseas | ||
| 05.11. | Novo Nordisk cuts guidance again on weaker GLP-1 growth | ||
| 04.11. | Bidding war breaks out as Novo raises Metsera bid to $10bn | ||
| 04.11. | Sarepta shares slide as DMD treatment woes pile up | ||
| 04.11. | UCB bags FDA okay for first drug to treat rare disease TK2d | ||
| 04.11. | Lilly reveals $3bn orforglipron facility in Netherlands |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .